Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2025-01-22 M&A Activity
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司关于双润正安信息咨询（北京）有限公司要约收购期满暨股票停牌的公告
M&A Activity Classification · 95% confidence The document is an official announcement from Jiangsu Haoubo Biopharmaceutical Co., Ltd. regarding the expiration of a tender offer period by Shuangrun Zheng'an Information Consulting (Beijing) Co., Ltd. and the related stock suspension and resumption. It details the tender offer terms, dates, and stock suspension information. There is no financial report or detailed financial data presented. The document is a formal notice about the tender offer completion and stock trading suspension/resumption, which fits the category of M&A Activity announcements related to takeover bids or tender offers.
2025-01-22 Chinese
江苏浩欧博生物医药股份有限公司关于注销部分募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the cancellation of certain special accounts for raised funds related to the company's initial public offering (IPO). It details the background of the fundraising, the management of the raised funds, and the specific accounts being closed because the related projects have been completed and funds fully used. The document is a formal public announcement about the status and management of capital raised, specifically about the closure of fundraising accounts. It does not contain financial statements, audit opinions, or detailed financial results. It is not a report like an Annual Report or Interim Report, nor is it a regulatory certification or legal proceeding. It fits best as a Capital/Financing Update (CAP) because it relates to the management and status of capital raised by the company and changes in the capital structure (closure of fundraising accounts). The document length is short (1864 characters), but it is a substantive announcement, not just a notice of report publication or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-01-17 Chinese
江苏浩欧博生物医药股份有限公司关于双润正安信息咨询（北京）有限公司要约收购公司股份的第三次提示性公告
M&A Activity Classification · 95% confidence The document is a detailed announcement regarding a third reminder for a tender offer (要约收购) by a company named 双润正安信息咨询（北京）有限公司 to acquire shares of 江苏浩欧博生物医药股份有限公司. It includes specifics such as the offer price, offer period, number of shares to be acquired, purpose of the offer, funding details, procedures for shareholders to accept or withdraw the offer, and current status of the tender offer. The document is not a financial report, earnings release, or management discussion, but rather a formal announcement related to a takeover bid. This fits the definition of M&A Activity (Code: TAR), which covers announcements and documents related to merger proposals or takeover bids. The document length is 3913 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the correct classification is TAR with high confidence.
2025-01-13 Chinese
江苏浩欧博生物医药股份有限公司关于自愿披露全资子公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding its wholly-owned subsidiary obtaining medical device registration certificates. It includes details about the certificates, their validity, and the expected impact on the company. The document is short (995 characters) and serves as a disclosure announcement about a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about a material event affecting the company.
2025-01-09 Chinese
华泰联合证券有限责任公司关于双润正安信息咨询（北京）有限公司要约收购江苏浩欧博生物医药股份有限公司之独立财务顾问报告
M&A Activity Classification · 100% confidence The document is titled as an "Independent Financial Advisor Report" by Huatai United Securities Co., Ltd. regarding a partial tender offer (要约收购) by Shuangrun Zheng'an Information Consulting (Beijing) Co., Ltd. for Jiangsu Haoubo Biopharmaceutical Co., Ltd. The content includes detailed sections on the acquirers, shareholding structure, financial data, purpose and terms of the tender offer, and independent financial advisor opinions. It is a comprehensive advisory report prepared to provide independent opinions on the fairness and reasonableness of the tender offer and its impact on the company and shareholders. This type of document is a specialized financial advisory report related to a takeover bid or merger activity. It is not a general annual or interim report, nor a simple announcement or regulatory filing. The document is clearly related to M&A activity and tender offer filings. Therefore, the appropriate classification is "M&A Activity" (Code: TAR). The document length (15,000 characters) and detailed content confirm it is the full report, not just an announcement or summary.
2025-01-08 Chinese
江苏浩欧博生物医药股份有限公司董事会关于双润正安信息咨询（北京）有限公司要约收购事宜致全体股东的报告书
M&A Activity Classification · 95% confidence The document is a detailed report issued by the board of directors of Jiangsu HOB Biotech Group Corp. Ltd. regarding a tender offer (要约收购) by Shuangrun Zheng'an Information Consulting (Beijing) Co., Ltd. It includes extensive information about the tender offer, the parties involved, the company's financial data, shareholding structure, conflicts of interest, and board recommendations. The document is titled as a "Board of Directors' Report" on the tender offer and contains detailed disclosures required by securities regulations. It is not a simple announcement but a comprehensive report related to a takeover bid. This fits the category of M&A Activity (Code: TAR), which covers announcements and documents related to merger proposals or takeover bids. The document length (15,000 characters) and content confirm it is the full report, not just an announcement or summary. Therefore, the correct classification is TAR with high confidence.
2025-01-08 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.